Improvement in Smell Using Monoclonal Antibodies Among Patients With Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review

杜皮鲁玛 美波利祖马布 医学 苯拉唑马布 奥马佐单抗 鼻息肉 皮肤病科 哮喘 重症监护医学 内科学 免疫学 免疫球蛋白E 嗜酸性粒细胞 抗体
作者
B Barroso,Marcela Valverde‐Monge,Diana Betancor,Alicia Gómez‐López,Carlos Villalobos-Vilda,B González-Cano,J. Sastre
出处
期刊:Journal of Investigational Allergology and Clinical Immunology [ESMON Publicidad]
卷期号:33 (6): 419-430 被引量:15
标识
DOI:10.18176/jiaci.0939
摘要

Background: Impairment of smell is more commonly related to chronic rhinosinusitis with nasal polyps (CRSwNP) than without, especially when asthma and/or NSAID-exacerbated respiratory disease and type 2 inflammation are also present. Therapeutic options include intranasal and systemic corticosteroids, surgery, and, more recently, biological therapy. We summarize current knowledge on the effect of biologics on olfaction in patients with CRSwNP. Methods: We performed a systematic search of the PubMed and Cochrane databases from January 2001 to June 2022. The inclusion criteria were as follows: adult patients with CRS treated with dupilumab, omalizumab, mepolizumab, benralizumab, or reslizumab; and studies published in English reporting outcomes for sense of smell based on psychophysical and/or subjective tools. We excluded reports that did not assess CRSwNP, loss of smell evaluated with a method other than those accepted in the inclusion criteria, review articles, and expert opinions. No funding was received. Results: Dupilumab has demonstrated rapid and sustained long-term improvement in smell in clinical trials and in real life. Omalizumab improves smell at 24 weeks. This improvement is maintained in the long-term, although it is not clinically relevant. Mepolizumab and benralizumab improved smell in the long term based on a subjective scale. No studies examining the improvement in smell in patients with CRSwNP treated with reslizumab were found. Indirect comparisons by meta-analysis consistently conclude that dupilumab is the most effective biologic for improving impaired sense of smell. Conclusion: Dupilumab seems to be more efficacious for improving the sense of smell than omalizumab, mepolizumab, and benralizumab.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1900发布了新的文献求助10
刚刚
没烦恼发布了新的文献求助10
1秒前
土土b完成签到,获得积分10
1秒前
1秒前
JQK完成签到,获得积分10
2秒前
3秒前
3秒前
Joanna发布了新的文献求助20
4秒前
4秒前
小栗子发布了新的文献求助10
4秒前
4秒前
Code_king发布了新的文献求助10
5秒前
6秒前
skychen完成签到,获得积分20
6秒前
HoT发布了新的文献求助10
6秒前
7秒前
crab_ccchen完成签到 ,获得积分10
7秒前
chiyudawang完成签到,获得积分10
7秒前
情怀的应助被淡泊宁静采纳,获得30
8秒前
8秒前
Maestro_S的应助被苏幕遮采纳,获得10
9秒前
9秒前
吴鹏完成签到,获得积分10
11秒前
小张完成签到 ,获得积分10
11秒前
Cqy完成签到,获得积分10
12秒前
科研通AI6.4的应助被Code_king采纳,获得10
13秒前
叶95发布了新的文献求助10
13秒前
科研通AI6.2的应助被Code_king采纳,获得10
13秒前
JeanetteJin发布了新的文献求助10
15秒前
16秒前
CTx发布了新的文献求助10
16秒前
alysia完成签到 ,获得积分10
17秒前
18秒前
19秒前
20秒前
20秒前
Owen的应助被科研通管家采纳,获得10
20秒前
JamesPei的应助被科研通管家采纳,获得10
20秒前
乐乐的应助被科研通管家采纳,获得10
20秒前
Jasper的应助被科研通管家采纳,获得10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177654
求助须知:如何正确求助?哪些是违规求助? 9568503
关于积分的说明 21799551
捐赠科研通 7772253
什么是DOI,文献DOI怎么找? 3432428
关于科研通互助平台的介绍 2556594
邀请新用户注册赠送积分活动 2478011